Sirolimus Tablet
NDC Package 70518-3795-0
Package Information
Sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants.In patients at low- to moderate-immunologic risk,it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see Dosage and Administration ( 2.2) ]. In patients at high-immunologic risk (defined as Black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [PRA; peak PRA level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see Dosage and Administration ( 2.3), Clinical Studies (14.3)]. This formulation utilizes a tablet delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-3795 and is authorized under FDA application ANDA201578.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70518 - Remedyrepack Inc.
- 70518-3795 - Sirolimus
- 70518-3795-0 - 100 POUCH in 1 BOX / 1 TABLET in 1 POUCH (70518-3795-1)
- 70518-3795 - Sirolimus
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70518-3795-0 identifies a specific commercial package of 100 pouch in 1 box / 1 tablet in 1 pouch (70518-3795-1) of Sirolimus, a human prescription drug labeled by Remedyrepack Inc.. This tablet is formulated for oral use and contains sirolimus as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on July 17, 2023. The current certification is valid through December 31, 2027.
How is this Remedyrepack Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518379500. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.